Why Arena Pharma Is Winning Big With Its New Collaboration

Health and Healthcare

Published: November 15, 2018 9:15 am

Last Updated: January 11, 2020 2:51 pm

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) shares jumped early on Thursday after the company announced a new global license agreement with United Therapeutics Corp. (NASDAQ: UTHR). The goal of this collaboration is to develop Arena Pharma’s Phase 3 investigational drug candidate, ralinepag, for the treatment of pulmonary arterial hypertension (PAH).

Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag. In return, Arena will receive up to $1.2 billion, including an upfront payment of $800 million and potential milestone payments totaling up to $400 million, based on the achievement of certain regulatory events.

Additionally, Arena will receive low double-digit tiered royalties on annual net sales of ralinepag.

Management is confident that after achieving FDA approval via at least one of its several different potential regulatory pathways to success, this product will help more than 10,000 patients annually from the 2020s and well into the 2030s.

Amit D. Munshi, president and CEO of Arena, commented:

We believe ralinepag has the potential to transform the treatment of PAH. We are thrilled to partner with United Therapeutics, based on their long-standing, deep commitment to the PAH community. This transaction represents a significant milestone in the development of ralinepag and will strategically position Arena to aggressively advance our best-in-class pipeline, anchored by etrasimod and olorinab, with the focus and resources essential for long-term success.

Shares of Arena Pharma closed Wednesday at $32.52, with a 52-week range of $26.02 to $50.05. The stock has a consensus analyst price target of $61.67. Following the announcement, shares were up 15% at $37.50 in early trading indications Thursday.

United Therapeutics closed Wednesday at $110.97 a share, in a 52-week range of $100.57 to $152.55. The consensus analyst target is $125.64.

24/7 Wall St.
Warren Buffett and Berkshire Hathaway Make Major Changes to Equity Holdings

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.